PFM Health Sciences, LP Buys Erasca Inc, Caribou Biosciences Inc, Cytokinetics Inc, Sells , ACADIA Pharmaceuticals Inc, Myovant Sciences

• New Purchases: ERAS, CRBU, SOPH, CTLT, ISEE, STVN, SGHT, AVIR, DXCM, DCPH, VECT, BYSI, PRCT,
• Added Positions: CYTK, AZN, TMO, PEN, NVAX, HRTX, DVAX, UHS, JNCE, ALLO, ADAP, ICLR, MRTX,
• Reduced Positions: BIIB, GH, NBIX, SGEN, ICUI, MYGN, SNDX, CNC, NVRO, HZNP, RCUS, KRTX, HUM, MCK, ABBV,
• Sold Out: ALXN, ACAD, MYOV, BAX, ARNA, LH, CNST, BCRX, STTK, INNV, ATHA, ONEM, OSH, DOCS,

For the details of PFM Health Sciences, LP's stock buys and sells, go to https://www.gurufocus.com/guru/pfm+health+sciences%2C+lp/current-portfolio/portfolio

1. Horizon Therapeutics PLC (HZNP) - 1,561,290 shares, 5.31% of the total portfolio. Shares reduced by 1.64%
2. Outset Medical Inc (OM) - 2,966,712 shares, 4.55% of the total portfolio.
3. Eli Lilly and Co (LLY) - 525,455 shares, 3.77% of the total portfolio.
4. Arcus Biosciences Inc (RCUS) - 3,431,010 shares, 3.72% of the total portfolio. Shares reduced by 1.92%
5. Cytokinetics Inc (CYTK) - 3,159,701 shares, 3.51% of the total portfolio. Shares added by 87.30%

PFM Health Sciences, LP initiated holding in Erasca Inc. The purchase prices were between $17.43 and $24.34, with an estimated average price of $20.69. The stock is now traded at around $19.550000. The impact to a portfolio due to this purchase was 3.05%. The holding were 5,191,405 shares as of 2021-09-30.

PFM Health Sciences, LP initiated holding in Caribou Biosciences Inc. The purchase prices were between $15.75 and $30.29, with an estimated average price of $24.56. The stock is now traded at around $21.530000. The impact to a portfolio due to this purchase was 2.74%. The holding were 4,092,309 shares as of 2021-09-30.

PFM Health Sciences, LP initiated holding in Sophia Genetics SA. The purchase prices were between $15.18 and $19.77, with an estimated average price of $17.62. The stock is now traded at around $15.510000. The impact to a portfolio due to this purchase was 1.1%. The holding were 2,022,552 shares as of 2021-09-30.

PFM Health Sciences, LP initiated holding in Catalent Inc. The purchase prices were between $109.17 and $142.35, with an estimated average price of $124.9. The stock is now traded at around $131.400000. The impact to a portfolio due to this purchase was 0.73%. The holding were 177,800 shares as of 2021-09-30.

PFM Health Sciences, LP initiated holding in IVERIC bio Inc. The purchase prices were between $7.07 and $17.5, with an estimated average price of $10.82. The stock is now traded at around $16.480000. The impact to a portfolio due to this purchase was 0.57%. The holding were 1,138,112 shares as of 2021-09-30.

PFM Health Sciences, LP initiated holding in Stevanato Group SPA. The purchase prices were between $19.51 and $28.7, with an estimated average price of $23.62. The stock is now traded at around $22.050000. The impact to a portfolio due to this purchase was 0.43%. The holding were 549,002 shares as of 2021-09-30.

PFM Health Sciences, LP added to a holding in Cytokinetics Inc by 87.30%. The purchase prices were between $18.54 and $35.74, with an estimated average price of $29.35. The stock is now traded at around $39.240000. The impact to a portfolio due to this purchase was 1.64%. The holding were 3,159,701 shares as of 2021-09-30.

PFM Health Sciences, LP added to a holding in AstraZeneca PLC by 276.68%. The purchase prices were between $55.56 and $60.79, with an estimated average price of $58.25. The stock is now traded at around $57.630000. The impact to a portfolio due to this purchase was 1.08%. The holding were 785,748 shares as of 2021-09-30.

PFM Health Sciences, LP added to a holding in Thermo Fisher Scientific Inc by 105.12%. The purchase prices were between $509.53 and $609.78, with an estimated average price of $548.6. The stock is now traded at around $641.480000. The impact to a portfolio due to this purchase was 0.65%. The holding were 71,442 shares as of 2021-09-30.

PFM Health Sciences, LP added to a holding in Penumbra Inc by 32.39%. The purchase prices were between $250.72 and $291.24, with an estimated average price of $268.99. The stock is now traded at around $265.420000. The impact to a portfolio due to this purchase was 0.36%. The holding were 177,088 shares as of 2021-09-30.

PFM Health Sciences, LP added to a holding in Novavax Inc by 32.26%. The purchase prices were between $177.8 and $270.58, with an estimated average price of $220.82. The stock is now traded at around $170.490000. The impact to a portfolio due to this purchase was 0.31%. The holding were 197,208 shares as of 2021-09-30.

PFM Health Sciences, LP added to a holding in Heron Therapeutics Inc by 36.13%. The purchase prices were between $10.13 and $15, with an estimated average price of $12.21. The stock is now traded at around $11.240000. The impact to a portfolio due to this purchase was 0.26%. The holding were 2,993,546 shares as of 2021-09-30.

PFM Health Sciences, LP sold out a holding in . The sale prices were between $179.45 and $186.61, with an estimated average price of $183.84.

PFM Health Sciences, LP sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $15.78 and $24.77, with an estimated average price of $19.31.

PFM Health Sciences, LP sold out a holding in Myovant Sciences Ltd. The sale prices were between $18.94 and $26.99, with an estimated average price of $22.04.

PFM Health Sciences, LP sold out a holding in Baxter International Inc. The sale prices were between $73.77 and $83.61, with an estimated average price of $79.12.

PFM Health Sciences, LP sold out a holding in Arena Pharmaceuticals Inc. The sale prices were between $45.8 and $71.24, with an estimated average price of $59.26.

PFM Health Sciences, LP sold out a holding in Laboratory Corp of America Holdings. The sale prices were between $274.82 and $308.34, with an estimated average price of $293.32.